6 October 2014Big Pharma

CleveXel granted licence for bone marrow cancer patents

Pharmaceutical company CleveXel Pharma has agreed a deal with a technology transfer company to licence two patents related to the treatment of bone marrow cancer.

The France-based company announced today (October 6) that it has been granted a licence by La Société d’Accélération du Transfert de Technologies Sud Est (Satt Sud Est) to exploit two new patents.

The first relates to the use of triazole nucleoside derivatives in the treatment of cancer, particularly azacitidine-resistant myelodysplastic syndromes.

Myelodysplastic syndromes are diseases that affect the bone marrow and can develop into leukemia.

The second patent concerns a test to identify the patients who are resistant to the standard azacitidine treatment, a chemotherapy drug.

Under the agreement, CleveXel will pay a percentage of its revenue to Satt Sud Est.

Christian Bloy, chairman and chief executive of CleveXel, said the partnership paved the way for innovation.

He added: “We are very pleased with this agreement, which provides an ideal opportunity to showcase this innovative project, as we fulfil unmet medical needs.”

Olivier Freneaux, chairman of Satt Sud Est, said it was confident the licence would be the first of a long lasting partnership.

Since it was established in 2012, Satt Sud Est has granted around 30 licenses.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk